Blood-based prediction and early detection of pancreatic cancer recurrence after tumor resection
The 5-year survival rate of patients with pancreatic ductal adenocarcinoma (PDAC) is < 8%. The best therapeutic option for PDAC is tumor resection. However, most patients experience recurrence within 2 years after surgery[1][1]. Postoperative monitoring includes CT imaging and determining CA19-9
Authors
- L. Sperling (ORCID: https://orcid.org/0000-0002-4250-777X)
- Henning Boekhoff (ORCID: https://orcid.org/0000-0003-4732-0661)
- Miriam Schenk (ORCID: https://orcid.org/0000-0003-0208-7958)
- Fawaz N. Al-Shaheri (ORCID: https://orcid.org/0000-0002-6857-2596)
- Teresa Colbatzky
- Christin Tjaden
- Chaoyang Zhang (ORCID: https://orcid.org/0000-0001-6816-3840)
- Natalia Giese
- Markus W. Büchler
- Mohamed S. S. Alhamdani
- Liang Xu
- Andrea S. Bauer
- Jörg D. Hoheisel
- Thilo Hackert
- Ulrike Heger
Institutions
- German Cancer Research Center (DE)
- Heidelberg University (DE)
- University Hospital Heidelberg (DE)
Publication Details
- Journal
- Cancer Biology and Medicine
- Published
- 2026-02-16
- DOI
- https://doi.org/10.20892/j.issn.2095-3941.2025.0495
- Primary Topic
- Pancreatic and Hepatic Oncology Research
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- Deutscher Akademischer Austauschdienst
- Bundesministerium für Bildung und Forschung
- China Scholarship Council